Drugs / GenSci144
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07685210 | Jun → Sep 2026 overdue | phenylketonuria | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-07-31 | Changchun GeneScience Pharmaceutical Co., Ltd. | Regulatory GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPA genscigroup.com ↗
Recently, GenSci144 tablets received IND approval from the National Medical Products Administration (NMPA) for the treatment of chronic kidney disease (CKD), following its previous trials for phenylketonuria(PKU). |
| 2025-10-24 | Changchun GeneScience Pharmaceutical Co., Ltd. | Results GenSci Announces Positive Phase II Results for GS1-144 Tablets in Chinese Postmenopausal Women with Moderate-to-Severe VMS genscigroup.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-31 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci144, a Novel SLC6A19 Inhibitor, Receives IND Approval from NMPA genscigroup.com ↗ |
| 2025-10-24 | Changchun GeneScience Pharmaceutical Co., Ltd. | GenSci Announces Positive Phase II Results for GS1-144 Tablets in Chinese Postmenopausal Women with Moderate-to-Severe VMS genscigroup.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenSci144 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07685210 ↗ |
| Action | Inhibit | “SLC6A19 transporter small molecule inhibitor” NCT07685210 ↗ |
| Modality | Small molecule | “SLC6A19 transporter small molecule inhibitor” NCT07685210 ↗ |
| Route | Oral | “oral tablets” NCT07685210 ↗ |
| Target | SLC6A19 | “SLC6A19 transporter small molecule inhibitor” NCT07685210 ↗ |